CM Hospitalar S/A (BVMF:VVEO3)
1.470
+0.020 (1.38%)
Last updated: Apr 28, 2026, 5:05 PM GMT-3
CM Hospitalar S/A Revenue
In the year 2025, CM Hospitalar S/A had annual revenue of 11.57B BRL, down -0.14%. CM Hospitalar S/A had revenue of 3.13B in the quarter ending December 31, 2025, with 6.68% growth.
Revenue
11.57B
Revenue Growth
-0.14%
P/S Ratio
0.04
Revenue / Employee
1.93M
Employees
6,000
Market Cap
464.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.57B | -16.45M | -0.14% |
| Dec 31, 2024 | 11.58B | 499.54M | 4.51% |
| Dec 31, 2023 | 11.08B | 2.34B | 26.72% |
| Dec 31, 2022 | 8.75B | 2.53B | 40.65% |
| Dec 31, 2021 | 6.22B | 1.81B | 40.91% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rede D'Or São Luiz | 55.73B |
| Raia Drogasil | 44.25B |
| Hypera | 7.70B |
| Fleury | 8.29B |
| Ouro Fino Saúde Animal Participações | 1.22B |
| Biomm | 269.30M |
| Profarma Distribuidora de Produtos Farmacêuticos | 11.45B |
| Qualicorp Consultoria e Corretora de Seguros | 1.43B |
CM Hospitalar S/A News
- 7 weeks ago - CM Hospitalar S/A Earnings Call Transcript: Q4 2025 - Transcripts
- 6 months ago - CM Hospitalar S/A Earnings Call Transcript: Q3 2025 - Transcripts
- 9 months ago - CM Hospitalar S/A Earnings Call Transcript: Q2 2025 - Transcripts
- 1 year ago - CM Hospitalar S/A Earnings Call Transcript: Q1 2025 - Transcripts
- 1 year ago - CM Hospitalar S/A Earnings Call Transcript: Q4 2024 - Transcripts
- 1 year ago - CM Hospitalar S/A Earnings Call Transcript: Q3 2024 - Transcripts
- 1 year ago - CM Hospitalar S/A Earnings Call Transcript: Q2 2024 - Transcripts